Immatics Initiates Personalized Adoptive Cellular Therapy in Patients with Relapsed And/Or Refractory Solid Cancers Using Its Pioneering Target Warehouse

Houston, Texas and Tuebingen, Germany, August 21, 2017 – Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrollment of patients into a phase I trial of its first adoptive cellular therapy (ACT) IMA101, using its...

read more

Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies

Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies
Arrangement Combines Immatics’ XPRESIDENT® Technology and Amgen’s Proprietary Bispecific Antibody Platform
Immatics to Receive $30 Million Upfront and Potentially Over $1 Billion in Milestone Payments Plus Royalties

read more

Immatics announces results of IMPRINT phase 3 clinical trial investigating the addition of IMA901 to standard first-line therapy with sunitinib for advanced/metastatic RCC

Immatics announces results of IMPRINT phase 3 clinical trial investigating the addition of IMA901 to standard first-line therapy with sunitinib for advanced/metastatic RCC

Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company and a global leader in cancer immunotherapy, announced today the results of a pivotal phase 3 clinical trial with IMA901

read more

Immatics and MD Anderson announce launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies

Immatics and MD Anderson announce launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies

Immatics US, Inc. has secured over $60m in total funding – more than $40m from the parent company Immatics Biotechnologies GmbH and a $19.7 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT)

read more